
Stephen V Liu/X
Apr 15, 2025, 08:23
Stephen V Liu: Taletrectinib and zidesamtinib promise to move the field of ROS1 NSCLC by addressing resistance and safety
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Dr. Yasir Elamin at TexasLung25 brings us up to speed on ROS1 NSCLC – highlighting resistance and safety.
Emerging agents like taletrectinib and zidesamtinib promise to move the field even further!”
More posts featuring TexasLung25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:43
Apr 19, 2025, 13:05